for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shionogi & Co Ltd

4507.T

Latest Trade

5,821.00JPY

Change

-29.00(-0.50%)

Volume

1,005,700

Today's Range

5,817.00

 - 

5,910.00

52 Week Range

5,503.00

 - 

7,796.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,850.00
Open
5,860.00
Volume
1,005,700
3M AVG Volume
18.80
Today's High
5,910.00
Today's Low
5,817.00
52 Week High
7,796.00
52 Week Low
5,503.00
Shares Out (MIL)
311.33
Market Cap (MIL)
1,844,012.00
Forward P/E
14.03
Dividend (Yield %)
1.61

Next Event

Dividend For 4507.T - 50.0000 JPY

Latest Developments

More

GSK Long-Acting HIV Injection Meets Goal In Late Stage Study

Shionogi & Co Adjusts Conversion Value For Euro-Yen Denominated Convertible Bonds Maturing In 2019

Shionogi & Co Ltd - Purchased All Outstanding Shares Of Pionnier Following Conclusion Of Latest Joint Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shionogi & Co Ltd

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company, mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides its products and services in Japan, Europe and North America markets.

Industry

Major Drugs

Contact Info

3-1-8, Dosho-machi, Chuo-ku

+81.6.62022161

http://www.shionogi.co.jp

Executive Leadership

Motozo Shiono

Chairman of the Board, Representative Director

Isao Teshirogi

President, Representative Director

Takuko Sawada

Vice President, Director

Takuo Fukuda

Senior Executive Officer

Koji Hanasaki

Senior Executive Officer

Key Stats

2.42 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.4K
EPS (JPY)

2017

259.880

2018

342.710

2019

424.308

2020(E)

414.897
Price To Earnings (TTM)
14.57
Price To Sales (TTM)
5.20
Price To Book (MRQ)
2.71
Price To Cash Flow (TTM)
12.80
Total Debt To Equity (MRQ)
0.13
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
18.67
Return on Equity (TTM)
16.77

Latest News

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

For much of its 141-year history, Japan's Shionogi & Co Ltd <4507.T> has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

Japanese drugmaker Shionogi sees record profit on royalty income

Japanese drugmaker Shionogi & Co Ltd forecast a 6.1 percent jump in full-year operating profit to what would be its fifth straight record high, underpinned by strong royalty income from its HIV drugs.

Japanese drugmaker Shionogi sees profit rising on royalty income

Japanese drugmaker Shionogi & Co Ltd expects its annual operating profit to rise 6.1 percent, it said on Thursday, underpinned by strong royalty income from its HIV drugs.

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

Shionogi aims to double flu-drug market with FDA-approved treatment

Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

FDA approves first new flu drug in almost two decades

Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

FDA approves blood disorder drug made by Japan's Shionogi

The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

BRIEF- Shionogi completes retirement of treasury shares

* Says it completed retirement of 5 million shares (1.5 percent stake) of its common stock on March 12

BRIEF-Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag

* SHIONOGI ANNOUNCES FDA NEW DRUG APPLICATION (NDA) AND EMA MARKETING AUTHORIZATION APPLICATION (MAA) ACCEPTANCES FOR LUSUTROMBOPAG (S-888711)

BRIEF-R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Shionogi to repurchase shares and retire treasury shares

* Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding

BRIEF-UMN Pharma says business and capital alliance with Shionogi

* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31

BRIEF-Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)

* Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States

BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​

* Shionogi & Co Ltd - Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Shionogi ‍announces positive top-line results for S-033188 phase 3 study

* Shionogi - announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients

BRIEF- Shionogi & lowers conversion price for 2019 due euro-yen denominated convertible bonds

* Says it lowers the conversion price for 2019 due euro-yen denominated convertible bonds to 4,150.9 yen per share, from 4,167.5 yen per share, effective April 1

BRIEF- PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi

* Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology

BRIEF-Takeda Pharmaceutical and Shionogi & Co to develop treatment techniques to combat Dementia- Nikkei

* Takeda Pharmaceutical and Shionogi & Co. with three other Japanese drug companies to develop treatment techniques to combat Dementia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up